Corcept Therapeutics (CORT) Cost of Revenue (2012 - 2026)

Corcept Therapeutics has reported Cost of Revenue for 15 years, with the latest figure at $4.1 million in Q2 2026.

• Quarterly Cost of Revenue rose 18.29% year-over-year to $4.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.1 million (up 20.81% YoY) and the FY2025 annual result came in at $13.0 million, up 19.25% from the prior year.
• Cost of Revenue improved to $4.1 million in Q2 2026 per CORT's latest filing, from $2.9 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $4.6 million in Q3 2025 and troughed at $1.2 million in Q1 2022.
• A 5-year average of $2.4 million and a median of $2.5 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue soared 82.9% in 2024, then dropped 13.9% in 2025.
• Over 5 years, Cost of Revenue stood at $1.5 million in 2022, then climbed by 26.82% to $1.9 million in 2023, then jumped by 57.49% to $3.0 million in 2024, then decreased by 13.9% to $2.5 million in 2025, then surged by 59.57% to $4.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.1 million, $2.9 million, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.